Janssen seeks US accelerated OK for drug-resistant TB treatment
This article was originally published in Scrip
Executive Summary
With the submission of its new drug application (NDA), Janssen Research & Development is asking the US FDA to grant accelerated approval for the use of bedaquiline (TMC207) as part of combination therapy for pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults.